Status:
UNKNOWN
Allogeneic HSCT in MDS Patients Based on Risk According to R-IPSS
Lead Sponsor:
University Of Perugia
Conditions:
MDS and Allogeneic Stem Cell Transplantation
Eligibility:
All Genders
Up to 70 years
Phase:
NA
Brief Summary
An "intention-to-treat" study to evaluate the impact of allogeneic HSCT with Total Marrow and Lymphoid irradiation (TMLI), followed by Treg/Tcon adoptive immunotherapy, on overall survival in patients...
Detailed Description
MDS patients with Intermediate, High, or Very-High R-IPSS risk will be enrolled. Allogeneic stem cell transplantation with regulatory and conventional T cell adoptive immunotherapy will be proposed to...
Eligibility Criteria
Inclusion
- Patients affected by Myelodysplastic Syndrome with IPSS-R INT, HIGH or VERY HIGH;
- Age \<71 years;
- Signature of the informed consent.
Exclusion
- Patients affected by Myelodysplastic Syndrome with IPSS-R VERY LOW or LOW;
- Patients affected by Myelodysplastic Syndrome/Myeloproliferative Neoplasm;
- Age \>70 years;
- No signature of the informed consent
Key Trial Info
Start Date :
September 20 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 19 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04801563
Start Date
September 20 2019
End Date
September 19 2025
Last Update
March 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Perugia
Perugia, PG, Italy, 06132